Trial Profile
An Optional Research Study to Identify Potential Biomarkers of Response to Peptide Immunotherapy for Ragweed Allergy in Subjects Already Enrolled in Clinical Study TR002
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Aug 2023
Price :
$35
*
At a glance
- Drugs Ragweed SPIRE (Primary)
- Indications Ragweed pollen hypersensitivity
- Focus Biomarker; Therapeutic Use
- Sponsors Circassia; Niox
- 24 Nov 2014 New trial record